Erratum to: Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment

@inproceedings{Weinreb2012ErratumTL,
  title={Erratum to: Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment},
  author={Neal J Weinreb and Jack Goldblatt and J. E. Villalobos and Joel Charrow and J. Alexander Cole and Marcelo Soares Kerstenetzky and Stephan vom Dahl and Carla E. M. Hollak},
  booktitle={Journal of Inherited Metabolic Disease},
  year={2012}
}
We studied the effect of long-term alglucerase/imiglucerase (Ceredase®/Cerezyme®, Genzyme, a Sanofi company, Cambridge, MA, USA) treatment on hematological, visceral, and bone manifestations of Gaucher disease type 1 (GD1). The International Collaborative Gaucher Group (ICGG) Gaucher Registry identified GD1 patients treated with alglucerase/imiglucerase who had dose and clinical data at first infusion and after 10 years of follow-up. Data for hemoglobin, platelet count, organ volumes, bone pain… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Gaucher disease: Phenotypic and genetic variation

  • G Grabowski, E Kolodny, N Weinreb, B Rosenbloom, A Prakash-Cheng, P Kaplan
  • 2010
2 Excerpts

Similar Papers

Loading similar papers…